Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation.
Sign Up to like & getrecommendations! Published in 2017 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2017.04.008
Abstract: OBJECTIVE The objective of this study is to longitudinally analyze the uptake of [11C]PK11195-PET in multiple sclerosis patients after 3 and 6 months of natalizumab treatment. METHODS Eighteen MS patients, starting treatment with monocloncal anti-VLA-4,… read more here.
Keywords: sclerosis; enhancing lesions; pk11195 uptake; reduction pk11195 ... See more keywords